← Back to Search

Behavioural Intervention

Education and Reminders for Lung Cancer Screening

N/A
Recruiting
Led By Gelareh Sadigh, MD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 50-80 years of age
Be older than 18 years old
Must not have
Prior history of lung cancer
History of Alzheimer's disease or dementia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 3 months after last patient completion of follow-up
Awards & highlights

Summary

This trial aims to improve lung cancer screening among Hispanic/Latinx individuals, who currently have limited access to healthcare services. The study will test a multi-level intervention that includes notifying primary care providers about patients

Who is the study for?
This trial is for Hispanic individuals aged 50-80 who are current or former smokers (quit within the last 15 years) with a history of heavy smoking. They must have an upcoming primary care appointment and be able to speak English or Spanish. It's focused on those in Orange County attending UCI Health clinics.
What is being tested?
The study tests if reminders to patients and providers, patient education, and financial navigation aid can increase lung cancer screenings using low dose CT scans compared to enhanced usual care. The goal is early detection of lung cancer in the Hispanic community.
What are the potential side effects?
Since this trial involves educational interventions rather than medical treatments, there are no direct side effects from medications. However, participants may experience anxiety or stress related to screening outcomes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had lung cancer before.
Select...
I have been diagnosed with Alzheimer's disease or dementia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 3 months after last patient completion of follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 3 months after last patient completion of follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Patients' knowledge about lung cancer screening
Patients' perceived barriers of lung cancer screening
Patients' perceived benefits of lung cancer screening
+3 more
Other study objectives
Patients' experience with intervention
Providers experience with intervention

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B: Empower LatinxExperimental Treatment5 Interventions
* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Group II: Arm A: Enhanced Usual CareExperimental Treatment2 Interventions
Usual Care + Brief Educational Material
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient education
2011
Completed Phase 2
~9240

Find a Location

Who is running the clinical trial?

Radiological Society of North AmericaOTHER
25 Previous Clinical Trials
859 Total Patients Enrolled
University of California, IrvineLead Sponsor
559 Previous Clinical Trials
1,929,948 Total Patients Enrolled
Gelareh Sadigh, MDPrincipal InvestigatorUniversity of California, Irvine
2 Previous Clinical Trials
141 Total Patients Enrolled
~13 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top